LONDON & BRISBANE, Calif.--(BUSINESS WIRE)--GlaxoSmithKline plc (LSE/NYSE: GSK) and Innoviva, Inc. (NASDAQ: INVA) today announced that the US Food and Drug Administration (FDA) has approved an ...

The drug consists of fluticasone furoate, an inhaled corticosteroid (ICS), umeclidinium, a long-acting muscarinic antagonist, and vilanterol, a long-acting beta2-adrenergic agonist (LABA), delivered ...

COPD is a progressive lung disease, which is caused by long-term exposure to inhaled irritants that damage the lungs and airways. These irritants include cigarette smoke, breathing in second hand ...

Navigating FDA's rules to get a fixed-dose combination therapy for chronic obstructive pulmonary disease approved required a large study and a specific population. When GlaxoSmithKline designed the ...

GlaxoSmithKline has seized the initiative with its three-drug COPD inhaler Trelegy Ellipta despite some new competition from AstraZeneca. To cement its lead, GSK is looking for a first-of-its-kind ...

Submission supported by pivotal CAPTAIN study demonstrating statistically significant improvement in lung function compared with the ICS/LABA, Relvar/Breo Ellipta At least 30% of asthma patients ...

Phase III CAPTAIN study of Trelegy Ellipta in patients with asthma meets primary endpoint GlaxoSmithKline plc (LSE/NYSE: GSK) and Innoviva, Inc. (NASDAQ: INVA) today announced headline results from ...

Trelegy Ellipta is contraindicated in patients with severe hypersensitivity to milk proteins or any of the ingredients. LABA monotherapy increases the risk of serious asthma-related events. Trelegy ...

Results from a phase 3 trial evaluating Trelegy Ellipta in patients with uncontrolled asthma showed that the single inhaler triple therapy provided a significant improvement in lung function when ...

Please provide your email address to receive an email when new articles are posted on . The FDA has approved Trelegy Ellipta, once-daily, single-inhaler triple therapy, for the new indication of ...

NEW YORK, July 13, 2022 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it has agreed to acquire a royalty interest in TRELEGY ELLIPTA (Trelegy) from Theravance Biopharma, ...